VV Buchake, AP Muthal, RB Saudagar, RS Bachhav.
Email ID Not Available
V.V. Buchake, A.P. Muthal, R.B. Saudagar and R.S. Bachhav*
Kalyani Charitable Trust’s R.G.Sapkal College of Pharmacy, Sapkal Knowledge Hub. Anjaneri, Trimbakeshwar, Nashik 422 212.
Volume - 2,
Issue - 4,
Year - 2010
Alzheimer disease (AD), though not a life threatening disease but increase the morbidity rate of an individual. It can be very well correlated with the retrograde amnesia. But specifically as it is encountered in elder subjects, it is represented as Senile Dementia. The earliest observable symptoms are often mistakenly thought to be 'age-related' concerns, or manifestations of stress. In the early stages, the most commonly recognized symptom is memory loss, such as difficulty in remembering recently learned facts. When a doctor or physician has been notified, and AD is suspected, the diagnosis is usually confirmed with behavioral assessments and cognitive tests, often followed by a brain scan if available. As the disease advances, symptoms include confusion, irritability and aggression, mood swings, language breakdown and long-term memory loss is also assumed. Gradually, bodily functions are lost, ultimately leading to death. It is found that some plaque is present in the brain. One area of clinical research is focused on treating the underlying disease pathology by reduction of amyloid beta levels is a common target of compounds under investigation. Immunotherapy or vaccination for the amyloid protein is one treatment modality under study. Unlike preventative vaccination, the putative therapy would be used to treat people already diagnosed.
Cite this article:
VV Buchake, AP Muthal, RB Saudagar , RS Bachhav. A Neurodegenerative disorder-Alzheimer disease: A Treatise. Research J. Pharmacology and Pharmacodynamics. 2010; 2(4): 268-273.